Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants Journal Article uri icon
  • OBJECTIVE: To assess the reversibility of the elevation of serum creatinine levels in patients with diabetes after 5 years of continuous on-trial fenofibrate therapy. RESEARCH DESIGN AND METHODS: An on-drug/off-drug ancillary study to the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Trial to investigate posttrial changes in serum creatinine and cystatin C. Eligible participants were recruited into a prospective, nested, three-group study based on retrospective on-trial serum creatinine levels: fenofibrate case subjects (n = 321, >/= 20% increase after 3 months of therapy); fenofibrate control subjects (n = 175, /= 20%) returned to the same level of renal function as participants receiving placebo while participants who had

  • Link to Article
    publication date
  • 2012
  • published in
  • Diabetes care  Journal
  • Research
  • Adverse Effects
  • Blood
  • Diabetes
  • Drugs and Drug Therapy
  • Kidney Diseases
  • Randomized Controlled Trials
  • Additional Document Info
  • 35
  • issue
  • 5